Frontlight ResearchEarly access
WithdrawnNo phase
A Study of Focal Salvage High-Dose-Rate Brachytherapy for Prostate Gland Only Recurrence
Key facts
- Who runs it
- University of Rochester
- Where
- Rochester, United StatesSee the site
- Trial code
- Status
- Withdrawn
- Started
- 29 Oct 2021
- Ended
- 4 Aug 2025
- Type of study
- Interventional
- Treatments tested
- High-Dose-Rate Brachytherapy
- Record updated
- 15 October 2025
- Why it stopped
- study stopped early, did not enroll anyone, and will not resume
Who can take part
- Age
- 18 years and older
- Sex
- Men only
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 2 criteriaShow less
Who can take part
- History of histologically confirmed, clinically localized adenocarcinoma of the prostate treated with external beam radiation, brachytherapy, or combination of external beam radiation and brachytherapy, with curative intent completed at least 24 months ago F-18 fluciclovine (AXUMIN) PET scan within 90 days prior to registration demonstrating recurrent lesion within the prostate gland Biopsy confirmation of disease recurrence within the prostate gland Age ≥ 18 KPS ≥ 70% Suitable candidate for brachytherapy based on established criteria IPSS score <16 No pelvic arch interference No Rectal fistula/fissure Fit for general or spinal anesthesia No history of urethral stricture Ability to understand, and willingness to sign the written informed consent
Who cannot take part
- Evidence of metastatic or nodal disease outside of the prostate gland on AXUMIN PET scan within 90 days prior to enrollment Patient unable to have MRI Patients with neuroendocrine or small cell carcinoma of the prostate TURP within 6 months prior to enrollment History of Crohn's disease, ulcerative colitis, or known radiation proctitis Inability to understand spoken and written English
Where in United States
- University of RochesterRochester, United States
About the trial
What the trial wants to find out
The purpose of this study is to learn more about what effects the use of high-dose-rate (HDR) brachytherapy on prostate cancer recurrence, seen by AXUMIN PET scan, has on prostate cancer.
The group in the trial
- Experimental: High-Dose-Rate prostate brachytherapyTreatment being tested
High-Dose-Rate brachytherapy, 2 fractions
Treatment: High-Dose-Rate Brachytherapy
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.
- Official title
- A Pilot Study of Focal Salvage High-Dose-Rate Brachytherapy for Prostate Gland Only Recurrence
- Record updated
- 15 October 2025